English  |  正體中文  |  简体中文  |  Items with full text/Total items : 90429/105609 (86%)
Visitors : 10511735      Online Users : 362
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version


    Please use this identifier to cite or link to this item: http://asiair.asia.edu.tw/ir/handle/310904400/101791


    Title: Association between antiepileptic drugs and hepatocellular carcinoma in patients with epilepsy: a population- based case–control study
    Authors: DongZongHung;Hung, Dong-Zong;Lin, Cheng-Li;Lin, Cheng-Li;Li, Yi-Wen;Li, Yi-Wen;Lin, Yen-Ning;Lin, Yen-Ning;Lee, Ying-Ray;Lee, Ying-Ray;王昭能;Wang, Charles C.N.;Che, Jih-Jung;Chen, Jih-Jung;Lim, Yun-Ping;Lim*, Yun-Ping
    Contributors: 生物資訊與醫學工程學系
    Date: 2016-09
    Issue Date: 2016-12-05 14:15:03 (UTC+8)
    Abstract: BACKGROUND:

    This study explored whether antiepileptic drugs (AEDs) use increases the risk of hepatocellular carcinoma (HCC).

    METHODS:

    We conducted a case-control study using data from the National Health Insurance system of Taiwan. The case group comprised 1,454 epilepsy patients with newly diagnosed HCC, and the control group comprised 1,448 epilepsy patients without HCC. Both groups had similar distributions of sex and age, and follow-up duration. Possible associations with the AEDs in Taiwan were examined.

    RESULTS:

    After adjusted for AEDs (phenobarbital and primidone, clonazepam, clorazepate and diazepam, and other AEDs), and for the comorbidities of diabetes, chronic liver disease and cirrhosis, hepatitis B and C virus infection, and alcoholism, the odds ratio (OR) of HCC was 1.22 (95% confidence interval [CI]: 1.01-1.47) for the group of phenytoin users compared with nonphenytoin users. An annual means of 61-120, 121-180, and >180 of defined daily doses (DDDs) of phenytoin (OR: 4.07, 95% CI: 2.03-8.18; OR: 7.51, 95% CI: 3.03-18.7, and OR: 14.6, 95% CI: 7.88-26.9, respectively) were significantly correlated with the risk of HCC but not with a DDD of ≤60. Compared with nonphenytoin users, HCC patients who had used phenytoin within 1 year of HCC diagnosis were at a greatest risk of HCC (adjusted OR: 2.29, 95% CI: 1.71-3.08), followed by who had used phenytoin within 2 years of diagnosis (adjusted OR: 1.92, 95% CI: 1.44-2.56).

    CONCLUSION:

    The results indicate that high dose of phenytoin was associated with a statistically significant increased OR for HCC, which was not demonstrated for low-dose phenytoin.
    Relation: Brain and Behavior
    Appears in Collections:[生物資訊與醫學工程學系 ] 期刊論文

    Files in This Item:

    File SizeFormat
    index.html0KbHTML127View/Open


    All items in ASIAIR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback